Pfizer Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 1PFE.MI | SNY | GLAXO.NS | AZN | MRK | 0R1F.IL | |
|---|---|---|---|---|---|---|
| Market cap | 140.44B | 113.74B | 423.55B | 293.14B | 370.96B | 137.59B |
| P/E (TTM) | 41.1 | 23.6 | 36.9 | 26.7 | 151.9 | 17.3 |
| Forward P/E | — | 8.9 | 31.6 | 16.7 | 16.7 | — |
| Price/book | 1.9 | 1.4 | 22.5 | 5.7 | 8.9 | 4.2 |
| Dividend yield | 5.65% | 5.10% | 2.25% | 1.69% | 2.26% | 4.04% |
| 1-year change | +28.04% | −4.08% | −2.83% | +12.81% | +75.29% | +34.05% |
| Today | −2.32% | +4.72% | −1.25% | +2.79% | +3.93% | +2.89% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All 1PFE.MI news ›Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFO
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Pfizer hikes full-year outlook, taps company veteran as new CFO
Pfizer on Tuesday reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts. Pfizer also Tuesday announced that Cecile Guegan, who has held…
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. Dr. Albert Bourla, Chairman and CEO of Pfizer:…
Pfizer raises sales outlook to US$62B to US$64B
Adjusted earnings guidance rises to US$2.95 to US$3.05 a share as non-COVID products grow and Pfizer appoints a permanent CFO. A US$1.5 billion increase in the annual sales forecast's midpoint followed US$16.6 billion in third-quarter…
Pfizer Lifts 2026 Guidance and Names New CFO
Discover our top-rated, regulated brokers. Compare platforms, fees and features, and explore the latest broker offers. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of…
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results
The company spent $43 billion in 2023 to acquire cancer drugmaker Seagen and $10 billion for obesity drug developer Metsera last year. Pfizer's acquired products are increasingly contributing, but the longer-term growth story still…
Pfizer hikes 2026 outlook despite flat Q3 revenue: names new CFO
Pfizer hikes 2026 outlook: names new CFO (PFE:NYSE) Seeking Alpha After reporting better-than-expected Q3 2026 financials on Tuesday, Pfizer (PFE) hiked its full-year outlook even as its quarterly revenue remained relatively flat amid less…
Pfizer promotes insider to CFO
The New York-based pharmaceutical giant appointed Cecile Guegan to succeed former CFO Dave Denton, who left in August. Guegan will be navigating a pharmaceutical industry that faces rising skepticism around vaccines and drug-makers, driven…
Pfizer Names Cecile Guegan Chief Financial Officer
Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- 247wallst.com23
- theglobeandmail.com19
- fool.com17
- seekingalpha.com11
- marketscreener.com10
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.